Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + pyrotinib
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**sintilimab + pyrotinib** is a combination therapy under clinical investigation, particularly for HER2-positive malignancies. **Sintilimab** is a fully human anti-programmed death 1 (PD-1) monoclonal antibody that blocks the PD-1/PD-L1 pathway, restoring T-cell activity for immune-mediated tumor killing. **Pyrotinib** is an oral, irreversible tyrosine kinase inhibitor that targets both human epidermal growth factor receptor 2 (HER2) and EGFR pathways, inhibiting cancer cell proliferation. The combination is being studied for synergistic anti-tumor efficacy in HER2-positive cancers, such as advanced breast cancer and non-small-cell lung cancer (NSCLC)[4][8]. Both agents are products of Chinese pharmaceutical innovation, with sintilimab developed by Innovent Biologics and Eli Lilly, and pyrotinib by Jiangsu Hengrui Medicine. Primary indications include HER2-positive breast cancer and HER2-mutated NSCLC.
- Other names
- sintilimab + pyrotinib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sintilimab + pyrotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + pyrotinib.